Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATAI LIFE SCIENCES N.V.

(ATAI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Atai Life Sciences Announces the Launch of Psyprotix, to Develop A Precision Psychiatry Approach for Treatment-Resistant Depression

10/11/2021 | 08:00am EST

atai Life Sciences announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications. PsyProtix takes a precision psychiatry approach, an emerging field that aims to treat disorders by factoring each patient’s variability in genes, metabolism, environment, and lifestyle. Traditionally, psychiatric patients are diagnosed and treated based on guidelines and protocols designed for the majority, which can often lead to trial and error as physicians attempt to best meet each individual patient’s needs. Precision psychiatry is designed to allow physicians to prescribe treatments specifically targeted to the individual, rather than relying on the trial and error approach and/or adding on treatments, such as antidepressants or antipsychotics, in the quest to achieve a therapeutic benefit. Over 300 million people suffer with a major depressive disorder (MDD) worldwide, with a third of these patients diagnosed with TRD. Direct medical costs for TRD patients are estimated to be two to three times higher than non-TRD MDD patients. These statistics highlight the importance and potential of a mechanistically targeted therapeutic approach. PsyProtix will focus on metabolomic mechanisms underlying depression symptoms for certain patients with the goal of deriving more tailored treatments.


ę S&P Capital IQ 2021
All news about ATAI LIFE SCIENCES N.V.
11/30Maxim Group Initiates Coverage on Atai Life Sciences With Buy Rating, $25 Price Target
MT
11/29Atai Life Sciences Boosts Stake in Compass Pathways
MT
11/29Atai Life Sciences Increases its Ownership Position in COMPASS Pathways
AQ
11/22HC Wainwright Adjusts Atai Life Sciences to $50 From $40, Reiterates Buy Rating
MT
11/17Berenberg Bank Adjusts Atai Life Sciences' Price Target to $38 From $35, Maintains Buy ..
MT
11/16RBC Trims Price Target on Atai Life Sciences to $17 From $19, Maintains Sector Perform ..
MT
11/15ATAI LIFE SCIENCES N.V. Management's Discussion and Analysis of Financial Condition an..
AQ
11/15European ADRs Move Slightly Higher in Monday Trading
MT
11/15ATAI Life Sciences' Q3 Loss Narrows
MT
11/15ATAI LIFE SCIENCES N : Reports Third Quarter 2021 Financial Results and Corporate Update -..
PU
More news
Analyst Recommendations on ATAI LIFE SCIENCES N.V.
More recommendations
Financials (USD)
Sales 2021 18,5 M - -
Net income 2021 -118 M - -
Net cash 2021 407 M - -
P/E ratio 2021 -13,2x
Yield 2021 -
Capitalization 1 760 M 1 760 M -
EV / Sales 2021 72,9x
EV / Sales 2022 23 408x
Nbr of Employees 35
Free-Float 90,8%
Chart ATAI LIFE SCIENCES N.V.
Duration : Period :
Atai Life Sciences N.V. Technical Analysis Chart | ATAI | NL0015000DX5 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 10,98 $
Average target price 29,92 $
Spread / Average Target 173%
EPS Revisions
Managers and Directors
Florian Brand Chief Executive Officer
Gregory L. Weaver Chief Financial Officer
Srinivas G. Rao Chief Scientific Officer
Rolando GutÝerrez-Esteinou Chief Medical Officer
Alexis Marc Joel Louis de Rosnay Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ATAI LIFE SCIENCES N.V.0.00%1 760
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
IQVIA HOLDINGS INC.44.63%49 504
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-42.34%23 827